natgillin/translations-raw huggingface dataset:
By contrast, evaluation of the steady-state plasma tipranavir trough concentrations at 10-14 h after dosing from the RESIST-1 and RESIST-2 studies demonstrate that females generally had higher tipranavir concentrations than males. 
Za razliku od toga, ocjena minimalnih koncentracija tipranavira u plazmi pri stanju ravnoteže, 10-14 sati nakon doziranja, iz RESIST-1 i RESIST-2 ispitivanja pokazuje da su žene općenito imale više koncentracije tipranavira nego muškarci.
Peak plasma concentrations are reached within 1 to 5 hours after dose administration depending upon the dosage used. 
Maksimalne koncentracije u plazmi postižu se u roku 1 do 5 sati nakon primjene, ovisno o dozi.
The exact dose should be measured using the supplied measuring syringe and adapter, as follows: 
Potrebno je izmjeriti točnu dozu uz uporabu priložene mjerne štrcaljke i adaptera, kako slijedi:
There are no data available indicating that omeprazole or esomeprazole dose adjustments will overcome the observed pharmacokinetic interaction. 
Ne postoje dostupni podaci koji ukazuju da će podešavanja doze omeprazola ili esomeprazola nadići primijećene farmakokinetičke interakcije.
The increase in carbamazepine total PK parameters is not expected to have clinical consequences. 
Ne očekuje se da povećanje ekspozicije karbamazepinu ima kliničke posljedice.
These effects are called interactions, and can lead to serious side effects, or prevent proper control of other conditions you may have. 
Ovi učinci se nazivaju interakcije, te mogu dovesti do teških nuspojava, ili spriječiti ispravnu kontrolu drugih stanja od kojih možda bolujete.
Most patients were able to continue treatment with tipranavir with ritonavir. 
Većina bolesnika mogla je nastaviti liječenje tipranavirom uz ritonavir.
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Efavirenz 600 mg QD No clinically significant interaction is observed. 
Nenukleozidni inhibitori reverzne transkriptaze (NNRTI) Efavirenz 600 mg QD Nije primijećena klinički značajna interakcija.
The development of resistance to tipranavir in vitro is slow and complex. 
Razvoj rezistencije na tipranavir in vitro je spor i složen.
In a pharmacokinetic study of healthy volunteers, boceprevir decreased the exposure of ritonavir, and some ritonavir-boosted protease inhibitors. 
U farmakokinetičkom ispitivanju na zdravim dobrovoljcima, boceprevir je smanjio izloženost ritonaviru i nekim ritonavirom pojačanim inhibitorima proteaze.
Aptivus should neither be used by children under 2 years of age nor by adolescents 12 years of age or older. 
Djeca i adolescenti Aptivus se ne primjenjuje u djece mlađe od 2 godine niti u adolescenata u dobi od 12 i više godina.
In vitro, there is an inverse correlation between the degree of resistance to tipranavir and the capacity of viruses to replicate. 
In vitro postoji inverzna korelacija između stupnja rezistencije na tipranavir i kapaciteta replikacije virusa.
Discuss with your child's doctor the precautions needed to avoid infecting other people. 
Razgovarajte s liječnikom svog djeteta o mjerama opreza koje morate poduzeti kako se ne bi zarazile druge osobe.
Tipranavir is a non-peptidic inhibitor of the HIV-1 protease that inhibits viral replication by preventing the maturation of viral particles. 
Tipranavir je nepeptidni inhibitor HIV-1 proteaze, koji inhibira replikaciju virusa tako što sprječava sazrijevanje virusnih čestica.
You must take Aptivus together with: 
Aptivus se mora uzimati zajedno s:
The clinical impact of the observed data, especially regarding the tipranavir with ritonavir safety profile, remains unknown. 
Klinički utjecaj primijećenih podataka, osobito s obzirom na profil sigurnosti tipranavira s ritonavirovim, ostaje nepoznat.
Fluconazole 200 mg QD (Day 1) then 100 mg QD 
Flukonazol 200 mg QD (1. dan) zatim 100 mg QD
Both of these factors may contribute to an increased risk of adverse reactions (type, frequency and/or severity). 
Oba ova čimbenika mogu doprinijeti povećanom riziku od nuspojava (tip, učestalost i/ili težinu).
Animal toxicology studies have been conducted with tipranavir alone, in mice, rats and dogs, and coadministered with ritonavir (3.75:1 w/w ratio) in rats and dogs. 
Toksikološka ispitivanja na životinjama izvođena su s monoterapijom tipranavirom na miševima, štakorima i psima, te u istodobnoj primjeni s ritonavirom (3,75:1 w/w omjer) na štakorima i psima.
The effects were reversible with termination of treatment. 
Učinci su se povukli po prekidu primjene lijeka.
Includes abdominal pain (N=1) and dyspepsia (N=1). 
Uključuje abdominalnu bol (n=1) i dispepsiju (n=1).
To be taken into account in pregnant or breast-feeding women, children and high-risk groups such as patients with liver disease, or epilepsy. 
Treba uzeti u obzir u trudnica, dojilja, djece te visokorizičnih skupina ljudi poput bolesnika s bolešću jetre ili epileptičara.
This score has been determined from the selected RESIST patient population having specific mutation inclusion criteria and therefore extrapolation to a wider population mandates caution. 
Skor je izveden na temelju podataka o bolesnicima iz RESIST ispitivanja koji su imali specifične kriterije uključivanja s obzirom na mutacije, te stoga ekstrapolacija na širu populaciju zahtijeva oprez.
Based on data from the cocktail study where caffeine (CYP1A2 substrate) AUC was reduced by 43%, tipranavir with ritonavir is expected to decrease theophylline concentrations. 
Temeljem podataka iz ispitivanja u kojem je AUC kofeina (CYP1A2 supstrat) bio smanjen za 43%, očekuje se da tipranavir s ritonavirom smanjuje koncentracije teofilina.
- if you have moderate to severe liver problems. 
- ako Vaše dijete ima umjerene do teške probleme s jetrom.
Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections and pneumocystis pneumonia. 
Relevantni primjeri su citomegalovirusni retinitis, generalizirane i/ili fokalne mikobakterijske infekcije, te pneumonija uzrokovana uzročnikom Pneumocystis.
At the age of 12 years, children treated with Aptivus should be switched from the oral solution to the capsules. 
U dobi od 12 godina djeca liječena Aptivusom prebacuju se s oralne otopine na kapsule.
If your child has liver disease or hepatitis, their doctor will decide if they need additional testing. 
Ako Vaše dijete ima bolest jetre ili hepatitis, liječnik će odlučiti treba li dodatno testiranje.
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment (see section 4.4). 
Također su prijavljeni autoimuni poremećaji (kao što su Gravesova bolest i autoimuni hepatitis); međutim, prijavljeno vrijeme do nastupa je varijabilnije te se ovi događaji mogu pojaviti više mjeseci nakon početka liječenja (vidjeti dio 4.4).
Until the bottle is exchanged the patient should continue to take the usual doses of the oral solution. 
Dok se boca ne zamijeni, bolesnik mora nastaviti s primjenom uobičajene doze oralne otopine.
Do NOT stop taking Aptivus unless your doctor instructs you to do so. 
NE prekidajte primjenu Aptivusa, osim ako Vas tako ne uputi liječnik.
There is no known antidote for tipranavir overdose. 
Ne postoji poznati antidot za predoziranje tipranavirom.
At 48-weeks the relative risk decreased to 1.27 (95% CI=0.76, 2.12). 
Nakon 48 tjedana, relativni rizik smanjio se na 1,27 (95% CI=0,76; 2,12).
Integrase strand transfer inhibitors Raltegravir 400 mg BID Raltegravir Cmax ↔ Raltegravir AUC 0-12↔ Raltegravir C12: ↓ 45% 
Inhibitori integraze Raltegravir 400 mg BID Raltegravir Cmax ↔ Raltegravir AUC 0-12↔ Raltegravir C12: ↓ 45%
Aptivus therapy should be discontinued in patients experiencing ASAT or ALAT elevations greater than 10X ULN, or developing signs or symptoms of clinical hepatitis during therapy. 
Terapiju Aptivusom treba prekinuti u bolesnika u kojih vrijednosti AST ili ALT narastu na više od 10 X GGN ili koji razviju znakove ili simptome kliničkog hepatitisa tijekom liječenja.
The most abundant urinary metabolite, at 11.0% of urine radioactivity (0.5% of dose) was a glucuronide conjugate of tipranavir. 
Najobilniji urinarni metabolit (11,0% radioaktivnosti urina, 0,5% doze), bio je glukuronidni konjugat tipranavira.
Paediatric population The oral solution has been shown to have greater bioavailability than the soft capsule formulation. 
Pedijatrijska populacija Pokazalo se da oralna otopina ima veću bioraspoloživost od mekih kapsula.
What you need to know before you take Aptivus 
Što morate znati prije nego počnete uzimati Aptivus
The potential net effect of tipranavir with ritonavir on CYP 2D6 is inhibition, because ritonavir is also a CYP 2D6 inhibitor. 
Potencijalni neto učinak tipranavira s ritonavirom na CYP 2D6 je inhibicija, jer je ritonavir također CYP 2D6 inhibitor.
Studies in human liver microsomes indicated tipranavir is an inhibitor of CYP 1A2, CYP 2C9, CYP 2C19 and CYP 2D6. 
Ispitivanja na mikrosomima ljudske jetre ukazala su da je tipranavir inhibitor CYP 1A2, CYP 2C9, CYP 2C19 i CYP 2D6.
Aptivus is specifically used for the treatment of HIV which is resistant to most other protease inhibitors. 
Aptivus se specifično primjenjuje u liječenju HIV-a koji je otporan na većinu drugih inhibitora proteaze.
After use of the oral syringe, replace the syringe cap. 
Nakon uporabe oralne štrcaljke, zamijenite kapicu štrcaljke.
Insert the oral syringe into the adapter located in the neck of the bottle. 
Umetnite oralnu štrcaljku u nastavak smješten u vratu boce.
According to current treatment guidelines, dual therapy with protease inhibitors is generally not recommended 
Prema trenutnim smjernicama za liječenje, općenito se ne preporučuje dvostruka terapija inhibitorima proteaze
Baseline phenotypic susceptibility was evaluated in 454 baseline patient samples. 
Početna fenotipska osjetljivost ocijenjena je na 454 bolesnička uzorka.
The majority of the effects in repeat-dose toxicity studies appeared at systemic exposure levels which are equivalent to or even below the human exposure levels at the recommended clinical dose. 
Većina učinaka u ispitivanjima toksičnosti ponavljanih doza pojavila se pri vrijednostima sistemske izloženosti koje su ekvivalentne ili čak ispod vrijednosti izloženosti u ljudi pri preporučenoj kliničkoj dozi.
In vitro metabolism studies with human liver microsomes indicated that CYP3A4 is the predominant CYP isoform involved in tipranavir metabolism. 
In vitro ispitivanja metabolizma s humanim jetrenim mikrosomima ukazala su da je CYP3A4 dominantna CYP-izoforma uključena u metabolizam tipranavira.
Tipranavir is a P-gp substrate, a weak P-gp inhibitor and appears to be a potent P-gp inducer as well. 
Tipranavir je Pgp-supstrat, slab P-gp-inhibitor, te se također smatra snažnim P-gp-induktorom.
Sedatives/hypnotics Midazolam 2 mg QD (iv) 
Sedativi/hipnotici Midazolam 2 mg QD (i.v.)
Protease inhibitors other than those listed above 
Inhibitori proteaze osim prethodno navedenih
Number of patients Primary efficacy endpoint: % with VL < 400 
Ishod primarne djelotvornosti: % s brojem kopija < 400
Patients receiving Aptivus or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV-1 infection. 
Bolesnici koji dobivaju Aptivus ili neko drugo antiretrovirusno liječenje mogu nastaviti razvijati oportunističke infekcije i druge komplikacije HIV-1 infekcije.
If you stop taking Aptivus 
Ako prestanete uzimati Aptivus
Doses of ritonavir lower than 200 mg twice daily should not be used as they might alter the efficacy profile of the combination. 
Doze ritonavira niže od 200 mg dvaput dnevno se ne smiju primjenjivati jer mogu promijeniti profil djelotvornosti kombinacije.
Tipranavir inhibits the replication of laboratory strains of HIV-1 and clinical isolates in acute models of T-cell infection, with 50% and 90% effective concentrations (EC50 and EC90) ranging from 0.03 to 0.07 µM (18-42 ng/ml) and 0.07 to 0.18 µM (42-108 ng/ml), respectively. 
Tipranavir inhibira replikaciju laboratorijskih sojeva HIV-1 i kliničkih izolata u akutnim modelima Tstanične infekcije, s djelotvornim koncentracijama 50% (EC50) i 90% (EC90) u rasponu od 0,03 do 0,07 µM (18-42 ng/ml), odnosno od 0,07 do 0,18 µM (42-108 ng/ml).
There are no adequate data from the use of tipranavir in pregnant women. 
Nema odgovarajućih podataka o primjeni tipranavira u trudnica.
Theophylline plasma concentrations should be monitored during the first two weeks of co-administration with Aptivus, co-administered with low dose ritonavir, and the theophylline dose should be increased as needed. 
Koncentracije teofilina u plazmi moraju se pratiti tijekom prva dva tjedna istodobne primjene s Aptivusom s niskom dozom ritonavira, a doza teofilina se mora povisiti, prema potrebi.
From clinical samples of healthy volunteers and HIV-1 positive subjects who received tipranavir without ritonavir the mean fraction of tipranavir unbound in plasma was similar in both populations (healthy volunteers 0.015%  0.006%; HIV-positive subjects 0.019%  0.076%). 
Iz kliničkih uzoraka zdravih dobrovoljaca i HIV-1 pozitivnih osoba, koji su dobivali tipranavir bez ritonavira, prosječna frakcija nevezanog tipranavira u plazmi bila je slična u obje skupine (zdravi dobrovoljci 0,015%  0,006%; HIV-pozitivni bolesnici 0,019%  0,076%).
Monitoring of digoxin serum concentrations is recommended until steady state has been obtained. 
Preporučuje se praćenje koncentracija digoksina u serumu do postizanja stanja ravnoteže.
Aptivus should only be used as part of an active combination antiretroviral regimen in patients with no other therapeutic options. 
Aptivus se primjenjuje isključivo kao dio aktivnog kombiniranog antiretrovirusnog režima u bolesnika bez drugih terapijskih opcija.
This medicinal product contains 7 vol % ethanol (alcohol), i.e. up to 400 mg per daily dose, equivalent to 8 ml of beer, or less than 4 ml of wine. 
Ovaj lijek sadrži 7 vol. % etanola (alkohola), tj. do 400 mg po dnevnoj dozi, što odgovara 8 ml piva, ili manje od 4 ml vina.
Nucleoside analogue DNA polymerase inhibitors Valaciclovir 500 mg single dose 
Nukleozidni inhibitori DNA polimeraze Valaciklovir 500 mg jednokratna doza
An increased risk of ICH has previously been observed in patients with advanced HIV disease/AIDS such as those treated in the Aptivus clinical trials. 
Povećani rizik ICH prethodno je primijećen u bolesnika s uznapredovalom HIV bolešću/AIDS-om poput onih koji su dobivali Aptivus u kliničkim ispitivanjima.
If your child forgets to take Aptivus 
Ako Vaše dijete zaboravi uzeti Aptivus
RESIST data also demonstrate that tipranavir co-administered with low dose ritonavir exhibits a better treatment response at 48 weeks when the OBR contains genotypically available antiretroviral agents (e.g. enfuvirtide). 
Podaci iz RESIST-a također pokazuju da tipranavir s niskom dozom ritonavira pokazuje bolji učinak nakon 48 tjedana kada OBR sadrži antiretrovirusne lijekove sukladne genotipu virusa (npr. enfuvirtid).
No studies have been conducted to determine the distribution of tipranavir into human cerebrospinal fluid or semen. 
Nije ispitana distribucija tipranavira u humani cerebrospinalni likvor ili sjemenu tekućinu.
Aptivus is not a cure for HIV-1 infection or AIDS. 
Aptivus ne može izliječiti infekciju virusom HIV-1 ili AIDS.
Aptivus should only be used as part of an active combination antiretroviral regimen in patients with no other therapeutic options (see sections 4.4 and 5.1). 
Aptivus se primjenjuje isključivo kao dio aktivnog kombiniranog antiretrovirusnog režima u bolesnika bez drugih terapijskih opcija (vidjeti dijelove 4.4 i 5.1).
Therefore, routine measurement of coagulation parameters is not currently indicated in the management of patients on Aptivus. 
Stoga trenutno nije indicirano rutinsko mjerenje koagulacijskih parametara u zbrinjavanju bolesnika na Aptivusu.
A pharmacodynamic interaction study in healthy volunteers demonstrated that administration of loperamide and Aptivus, coadministered with low dose ritonavir, does not cause any clinically relevant change in the respiratory response to carbon dioxide. 
Ispitivanje farmakodinamičkih interakcija na zdravim dobrovoljcima pokazalo je da primjena loperamida i Aptivusa s niskom dozom ritonavira ne izaziva klinički značajne promjene u respiratornoj reakciji na CO2.
Dizziness, somnolence, and fatigue have been reported in some patients; therefore, caution should be recommended when driving a car or operating machinery. 
U nekih bolesnika primijećeni su omaglica, somnolencija i umor te se stoga treba preporučiti oprez pri upravljanju vozilima ili rukovanju sa strojevima.
In addition, reactivation of herpes simplex and herpes zoster has been observed in clinical studies with Aptivus, co-administered with low dose ritonavir. 
Nadalje, reaktivacija herpes simpleksa i herpes zostera primijećena je u kliničkim ispitivanjima uz Aptivus s niskom dozom ritonavira.
HIV-positive, paediatric patients, aged 2 through 18 years, were studied in a randomized, open-label, multicenter study (trial 1182.14). 
HIV-pozitivni pedijatrijski bolesnici, u dobi 2 do 18 godina, bili su uključeni u randomizirano, otvoreno, multicentrično kliničko ispitivanje (ispitivanje 1182.14).
emtricitabine: If your child is taking emtricitabine your child's kidney function should be checked before initiation of Aptivus. 
- emtricitabin: Ako Vaše dijete primjenjuje emtricitabin, potrebno je provjeriti bubrežnu funkciju Vašeg djeteta prije početka primjene Aptivusa.
Concomitant use of Aptivus/ritonavir caused a decrease of etravirine exposure that could significantly impair the virologic response to etravirine. 
Istodobna primjena Aptivusa/ritonavira izazvala je smanjenu izloženost etravirinu što može značajno smanjiti virološki odgovor na etravirin.
Tipranavir maintains significant antiviral activity (< 4-fold resistance) against the majority of HIV-1 clinical isolates showing post-treatment decreased susceptibility to the currently approved protease inhibitors: amprenavir, atazanavir, indinavir, lopinavir, ritonavir, nelfinavir and saquinavir. 
Tipranavir održava značajnu antivirusnu aktivnost (< 4-struka otpornost) protiv većine HIV-1 kliničkih izolata koji pokazuju smanjenu osjetljivost na trenutno odobrene inhibitore proteaze: amprenavir, atazanavir, indinavir, lopinavir, ritonavir, nelfinavir i sakvinavir.
Some of the side effects of Aptivus may affect your ability to drive or operate machinery (e.g. dizziness and sleepiness). 
Neke od nuspojava Aptivusa mogu utjecati na sposobnost upravljanja vozilima ili strojevima (npr. omaglica i snenost).
After use of the oral syringe, reapply the syringe cap. 
Nakon uporabe oralne štrcaljke, vratite kapicu štrcaljke.
In a pharmacokinetic study performed in healthy volunteers, concomitant use of low dose ritonavir (200 mg twice daily) with a single dose of trazodone led to an increased plasma concentration of trazodone (AUC increased by 2.4 fold). 
U farmakokinetičkom ispitivanju na zdravim dobrovoljcima, istodobna primjena niske doze ritonavira (200 mg dvaput dnevno) s jednokratnom dozom trazodona dovela je do povećanih koncentracija trazodona u plazmi (AUC povećan za 2,4 puta).
Tell your child's doctor or pharmacist if your child is taking, has recently taken or might take any other medicines, including medicines obtained without a prescription. 
Obavijestite djetetovog liječnika ili ljekarnika ako Vaše dijete uzima, ili je nedavno uzelo ili bi moglo uzeti bilo koje druge lijekove, uključujući i one koje se izdaju bez recepta.
Sustained HIV-1 RNA decreases up to week 48 were mainly observed in patients who received tipranavir with ritonavir and new enfuvirtide. 
Kontinuirano smanjenje HIV-1 RNA do 48. tjedna uglavnom je ostvareno u bolesnika koji su dobivali tipranavir s ritonavirom i novi enfuvirtid.
* see section Description of selected adverse reactions “Bleeding” for source of information 
* kao izvor informacija vidjeti dio: Opis odabranih nuspojava „Krvarenje“
The predominant effects of repeated administration of tipranavir across all species toxicologically tested were on the gastrointestinal tract (emesis, soft stool, diarrhoea) and the liver (hypertrophy). 
Dominantni učinci ponavljane primjene tipranavira na svim vrstama bili su učinci na gastrointestinalni sustav (emeza, mekana stolica, proljev) i jetru (hipertrofija).
No dosage adjustment necessary in patients with normal renal function. 
Nije potrebna prilagodba doze u bolesnika s urednom bubrežnom funkcijom.
Fluticasone propionate Interaction study performed only with ritonavir 
Flutikazonpropionat Ispitivanje interakcija provedeno samo s ritonavirom
In patients with a body surface area of less than 1.33 m2 appropriate dose adjustments cannot be achieved with the capsule formulation. 
Za bolesnike s tjelesnom površinom manjom od 1,33 m2 kapsulama se ne može postići odgovarajuće prilagođavanje doza.
If your child takes more Aptivus than he/she should Inform your child's doctor as soon as possible if they take more than the prescribed dose of Aptivus. 
Ako Vaše dijete uzme više Aptivusa nego što je trebalo Obavijestite djetetovog liječnika što je prije moguće ako Vaše dijete uzme više od propisane doze Aptivusa.
The most abundant faecal metabolite, at 4.9% of faecal radioactivity (3.2% of dose), was a hydroxyl metabolite of tipranavir. 
Najobilniji metabolit u stolici (4,9% radioaktivnosti, 3,2% doze), bio je hidroksilni metabolit tipranavira.
At 48-weeks in Phase III trials, rash of various types was observed in 15.5% males and 20.5% females receiving Aptivus coadministered with low dose ritonavir. 
Nakon 48 tjedana, u ispitivanjima faze III, različiti tipovi osipa opaženi su u 15,5% muškaraca i 20,5% žena koji su dobivali Aptivus s niskom dozom ritonavira.
Caution should be exercised when administering Aptivus to patients with liver enzyme abnormalities or with a history of hepatitis. 
Potreban je oprez prilikom primjene Aptivusa u bolesnika s abnormalnostima jetrenih enzima ili anamnezom hepatitisa.
Contains macrogolglycerol ricinoleate, sorbitol and ethanol (see package leaflet for further information) 
POPIS POMOĆNIH TVARI Sadrži makrogolglicerolricinoleat, sorbitol i etanol (vidjeti uputu o lijeku za dodatne informacije)
Data are not available to indicate whether tipranavir inhibits or induces glucuronosyl transferases. 
Nisu dostupni podaci koji bi ukazali inhibira li ili inducira tipranavir glukuronozil transferaze.
Your doctor will monitor your liver function by blood tests before and during Aptivus treatment. 
Liječnik će pratiti funkciju Vaše jetre putem testiranja krvi prije i tijekom liječenja Aptivusom.
Patients with mild hepatic impairment (Child-Pugh Class A) should be closely monitored. 
Bolesnici s blagim oštećenjem jetre (Child-Pugh stadij A) moraju se pomno pratiti.
Baseline HIV-1 RNA (log10 copies/ml) 
Početni HIV-1 RNA (log10 kopije/ml)
An increase in gastric pH that may result from H2-receptor antagonist therapy is not expected to have an impact on tipranavir plasma concentrations. 
Ne očekuje se da povećanje želučanog pH, koje može biti rezultat terapije antagonistom H2receptora, utječe na koncentracije tipranavira u plazmi.
If unavoidable, upward dose adjustments for either omeprazole or esomeprazole may be considered based on clinical response to therapy. 
Ako je nužno, može se razmotriti povišenje doze omeprazola ili esomeprazola, temeljem kliničkog odgovora na terapiju.
It may be difficult to tell the difference between: - side effects caused by Aptivus - side effects caused by the other medicines you are also taking - complications of HIV infection. 
Može biti teško naći razliku između: - nuspojava koje izaziva Aptivus - nuspojava izazvanih drugim lijekovima koje istodobno uzimate - komplikacija infekcije HIV-om.
Preclinical studies performed with tipranavir showed no adverse effect on fertility (see section 5.3). 
Pretklinička ispitivanja tipranavira nisu pokazala štetne učinke na plodnost (vidjeti dio 5.3).